Karolinska Development Future Growth
Future criteria checks 0/6
Karolinska Development is forecast to grow earnings and revenue by 5.8% and 1.8% per annum respectively while EPS is expected to grow by 6.2% per annum.
Key information
5.8%
Earnings growth rate
6.2%
EPS growth rate
| Pharmaceuticals earnings growth | 21.2% |
| Revenue growth rate | 1.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 18 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -24 | -25 | -25 | 1 |
| 12/31/2025 | 2 | -23 | -22 | -22 | 1 |
| 12/31/2024 | 2 | -24 | -23 | -23 | 1 |
| 9/30/2024 | 2 | -29 | -26 | -26 | N/A |
| 6/30/2024 | 2 | -6 | -24 | -24 | N/A |
| 3/31/2024 | 2 | 34 | -22 | -22 | N/A |
| 12/31/2023 | 2 | 5 | -25 | -25 | N/A |
| 9/30/2023 | 2 | 17 | -26 | -26 | N/A |
| 6/30/2023 | 2 | -41 | -27 | -27 | N/A |
| 3/31/2023 | 2 | -87 | -27 | -27 | N/A |
| 12/31/2022 | 2 | -88 | -33 | -33 | N/A |
| 9/30/2022 | 2 | -118 | -31 | -31 | N/A |
| 6/30/2022 | 2 | -72 | 10 | 10 | N/A |
| 3/31/2022 | 2 | 166 | 10 | 10 | N/A |
| 12/31/2021 | 2 | 171 | 17 | 17 | N/A |
| 9/30/2021 | 2 | 276 | 47 | 47 | N/A |
| 6/30/2021 | 2 | 108 | 2 | 2 | N/A |
| 3/31/2021 | 2 | -106 | -6 | -6 | N/A |
| 12/31/2020 | 3 | -207 | -33 | -33 | N/A |
| 9/30/2020 | 3 | 35 | -19 | -19 | N/A |
| 6/30/2020 | 3 | 190 | -41 | -41 | N/A |
| 3/31/2020 | 4 | 195 | -36 | -36 | N/A |
| 12/31/2019 | 3 | 303 | -7 | -7 | N/A |
| 9/30/2019 | 4 | -11 | -6 | -6 | N/A |
| 6/30/2019 | 4 | 8 | 18 | 18 | N/A |
| 3/31/2019 | 3 | 32 | 19 | 19 | N/A |
| 12/31/2018 | 3 | 31 | 13 | 13 | N/A |
| 9/30/2018 | 3 | 48 | -60 | -60 | N/A |
| 6/30/2018 | 3 | 238 | N/A | -56 | N/A |
| 3/31/2018 | 3 | 185 | N/A | -49 | N/A |
| 12/31/2017 | 2 | 180 | N/A | -31 | N/A |
| 9/30/2017 | 5 | 125 | N/A | -6 | N/A |
| 6/30/2017 | 5 | -87 | N/A | 3 | N/A |
| 3/31/2017 | 5 | -142 | N/A | 6 | N/A |
| 12/31/2016 | 5 | -217 | N/A | -9 | N/A |
| 9/30/2016 | 2 | -315 | N/A | -32 | N/A |
| 6/30/2016 | 2 | -325 | N/A | -95 | N/A |
| 3/31/2016 | 3 | -904 | N/A | -122 | N/A |
| 12/31/2015 | 3 | -1,055 | N/A | -325 | N/A |
| 9/30/2015 | 4 | -980 | N/A | -375 | N/A |
| 6/30/2015 | 5 | -1,072 | N/A | -342 | N/A |
| 3/31/2015 | 5 | -608 | N/A | -306 | N/A |
| 12/31/2014 | 5 | -371 | N/A | -108 | N/A |
| 9/30/2014 | 4 | -424 | N/A | -57 | N/A |
| 6/30/2014 | 5 | -396 | N/A | -124 | N/A |
| 3/31/2014 | 5 | -169 | N/A | -54 | N/A |
| 12/31/2013 | 5 | -157 | N/A | -71 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2I9 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2I9 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2I9 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2I9's revenue (1.8% per year) is forecast to grow slower than the German market (5.6% per year).
High Growth Revenue: 2I9's revenue (1.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2I9's Return on Equity is forecast to be high in 3 years time